Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 4/20 | 0.54 |
| ▸ | CRBN | Q96SW2 | 15/20 | 0.54 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.43 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.43 |
| ▸ | BTK | Q06187 | 4/20 | 0.42 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
| ▸ | IRAK3 | Q9Y616 | 1/20 | 0.40 |
| ▸ | HPGDS | O60760 | 1/20 | 0.40 |
| ▸ | PLK4 | O00444 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23134592 | 0.89 | CRBN (0.56) | ARCRBNDDB1IKZF3BTK | |
| SCHEMBL22692240 | 0.88 | CRBN (0.58) | ARCRBNDDB1IKZF3BTK | |
| SCHEMBL22645447 | 0.88 | CRBN (0.55) | ARCRBNDDB1BTKIRAK1 | |
| SCHEMBL22661366 | 0.88 | AR (0.54) | ARCRBNDDB1IKZF3BTK | |
| SCHEMBL31605511 | 0.87 | AR (0.65) | ARCRBNDDB1IKZF3BTK | |
| SCHEMBL31605518 | 0.87 | AR (0.65) | ARCRBNDDB1IKZF3BTK | |
| SCHEMBL25691074 | 0.87 | CRBN (0.54) | ARCRBNDDB1IKZF3BTK | |
| SCHEMBL31258560 | 0.84 | AR (0.64) | ARCRBNDDB1IKZF3BTK | |
| SCHEMBL22661322 | 0.82 | CRBN (0.55) | ARCRBNDDB1IKZF3BTK | |
| SCHEMBL22661395 | 0.82 | CRBN (0.55) | ARCRBNDDB1IKZF3BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230135173-A1 | NOVEL SUBSTITUTED QUINOLINE-8-CARBONITRILE DERIVATIVES HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2023-05-04 | — | — | US | disclosed |
| EP-3795570-A1 | SUBSTITUTED QUINOLINE-8-CARBONITRILE DERIVATIVES HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | Accutar Biotechnology Inc. (US) | 2021-03-24 | — | — | EP | disclosed |
| US-10836749-B1 | Substituted quinoline-8-carbonitrile derivatives having androgen receptor degradation activity and uses thereof | ACCUTAR BIOTECHNOLOGY INC. (US) | 2020-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230135173-A1 | NOVEL SUBSTITUTED QUINOLINE-8-CARBONITRILE DERIVATIVES HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | AR, NR5A1, ESRRA | AR 1/4885CRBN 409/4885DDB1 608/4885 |
| US-10836749-B1 | Substituted quinoline-8-carbonitrile derivatives having androgen receptor degradation activity and uses thereof | AR, NR5A1, ESRRA | AR 1/4885CRBN 357/4885DDB1 922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.